AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
April 22, 2020 08:05 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and PARIS, April 22, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company,...
Don Haut, PhD, Joins AskBio as Chief Business Officer
April 07, 2020 08:30 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy
March 12, 2020 09:11 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., March 12, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
CYTOO and AskBio Enter Research Agreement to Screen Gene Therapy Candidates for Rare Muscle Disorder
March 02, 2020 13:21 ET
|
Asklepios BioPharmaceutical, Inc.
GRENOBLE, France and RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research...
AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development
February 19, 2020 09:18 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure
February 04, 2020 08:05 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor...
AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 02, 2020 16:53 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
December 19, 2019 08:25 ET
|
Asklepios BioPharmaceutical, Inc.
– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...